Furthermore, PrognoScan GEO datasets revealed that EPHX2 was oncogenic in blood cancer and protective in colorectal, eye, lung, prostate, and soft tissue cancers (Figure S3). Here, EPHX2 is linked to hematopoietic and lymphoid system neoplasm.